Average Insider

Where insiders trade, we follow

$PTHS
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Healthcare
Sector
Biotechnology
Industry
Francis Knuettel II,
CEO
4
Employees
$21.48
Current Price
$8.90M
Market Cap
52W Low$18.19
Current$21.4817.0% above low, 83.0% below high
52W High$37.50

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells33$44,938.522,141
3 monthsBuys00--All Sells
Sells33$44,938.522,141
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Oct 2, 2026
Greenleaf Peter
Director
Sale797$21.17$16,872.49View Details
Oct 2, 2026
Friedberg Ezra M
Director
Sale558$20.72$11,560.03View Details
Oct 2, 2026
Pauls Matthew
Director
Sale786$21.00$16,506.00View Details
21 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 12, 2026
EPS
Estimated-$3.08
Actual-$2.04
Beat
Revenue
Estimated$16.92M
Actual$15.39M
Miss
2 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.11.1